Enterprise Value
151.9M
Cash
24.71M
Avg Qtr Burn
-7.517M
Short % of Float
0.42%
Insider Ownership
13.10%
Institutional Own.
19.29%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Gohibic (vilobelimab) Details COVID-19 | BLA Submission | |
Vilobelimab (IFX-1) Details Skin disease/disorder, Autoimmune disease | Phase 3 Initiation | |
Vilobelimab (IFX-1) Details Cancer, Cutaneous squamous cell carcinoma | Phase 2 Data readout | |
INF904 (C5aR Inhibitor) Details Chronic Autoimmune and Inflammatory Diseases | Phase 1a Data readout | |
IFX-1 (vilobelimab) Details Skin disease/disorder, Hidradenitis suppurativa | Failed Discontinued | |
IFX-1 (vilobelimab) Details Autoimmune disease, Antineutrophil cytoplasmic antibody-associated vasculitis | Failed Discontinued |